a Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology , Indian Institute of Technology (Banaras Hindu University) , Varanasi 221005 , India.
J Biomol Struct Dyn. 2019 Mar;37(4):944-965. doi: 10.1080/07391102.2018.1444510. Epub 2018 Mar 9.
Matrix metalloproteinase-9 (MMP-9) is a significant target for the development of drugs for the treatment of arthritis, CNS disorders, and cancer metastasis. The structure-based and ligand-based methods were used for the virtual screening (VS) of database compounds to obtain potent and selective MMP-9 inhibitors. Experimentally known MMP-9 inhibitors were used to grow up ligand-based three pharmacophore models utilizing Schrodinger suite. The X-ray crystallographic structures of MMP-9 with different inhibitors were used to develop five energy-optimized structure-based (e-pharmacophore) models. All developed pharmacophores were validated and applied to screen the Zinc database. Pharmacophore matched compounds were subjected to molecular docking to retrieve hits with novel scaffolds. The molecules with diverse structures, high docking scores and low binding energies for various crystal structures of MMP-9, were selected as final hits. The Induced fit docking (IFD) analysis provided significant information about the driving of inhibitor to approve a suitable bioactive conformational position in the active site of protein. Since charge transfer reaction occurs during receptor-ligand interaction, therefore, electronic features of hits (ligands) are interesting parameters to explain the binding interactions. Density functional theory (DFT) at B3LYP/6-31G* level was utilized to explore electronic features of hits. The docking study of hits using AutoDock was helpful to establish the binding interactions. The study illustrates that the combined pharmacophore approach is advantageous to identify diverse hits which have better binding affinity to the active site of the enzyme for all possible bioactive conformations. The approach used in the study is worthy to design drugs for other targets.
基质金属蛋白酶-9(MMP-9)是开发治疗关节炎、中枢神经系统疾病和癌症转移药物的重要靶点。本研究采用基于结构和基于配体的方法对数据库化合物进行虚拟筛选,以获得强效和选择性的 MMP-9 抑制剂。利用 Schrödinger 套件,使用实验已知的 MMP-9 抑制剂来构建基于配体的三个药效团模型。利用 MMP-9 与不同抑制剂的 X 射线晶体结构来开发五个能量优化的基于结构的(e-pharmacophore)模型。所有开发的药效团均经过验证,并应用于筛选 Zinc 数据库。与药效团匹配的化合物进行分子对接,以检索具有新型骨架的命中化合物。选择具有不同结构、对 MMP-9 各种晶体结构具有较高对接分数和较低结合能的分子作为最终命中化合物。诱导契合对接(IFD)分析提供了关于抑制剂驱动的重要信息,以批准蛋白质活性位点中合适的生物活性构象位置。由于受体-配体相互作用过程中发生电荷转移反应,因此,配体的电子特征是解释结合相互作用的有趣参数。采用 B3LYP/6-31G*水平的密度泛函理论(DFT)研究配体的电子特征。使用 AutoDock 对接配体有助于建立结合相互作用。研究表明,组合药效团方法有利于识别具有更好结合亲和力的不同配体,这些配体对酶的所有可能的生物活性构象都具有更好的结合亲和力。该研究中使用的方法值得用于设计针对其他靶点的药物。